Study finds a cause of resistance to revumenib in acute leukemia

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

November 22, 2024

Vol.50 No.44

In Brief

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.

November 15, 2024

Vol.50 No.43

Drugs & Targets

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

November 08, 2024

Vol.50 No.42

Clinical Roundup

RAS-mutant leukemia stem cells behave differently from other leukemia stem cells

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia and its resistance to a common treatment. The study, published Oct. 30 in Nature, was led by Eirini Papapetrou, professor of oncological sciences at Icahn Mount Sinai. Acute myeloid leukemia is a devastating blood cancer that starts in...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Tracing cancer back to birth uncovers promising biomarkers for prevention, early detection, targeted treatment of childhood leukemia

Molecular markers in blood at birth are linked to later development of acute lymphoblastic leukemia, the most common cancer type that affects children, according to a study published in Molecular Cancer.

October 25, 2024

Vol.50 No.40

Study finds a cause of resistance to revumenib in acute leukemia

YOU MAY BE INTERESTED IN

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

Ruxolitinib improves CML’s response to standard TKI treatment

RAS-mutant leukemia stem cells behave differently from other leukemia stem cells

Tracing cancer back to birth uncovers promising biomarkers for prevention, early detection, targeted treatment of childhood leukemia

Renew today!

Subscriber content

Never miss an issue!

Login